Market closed

Akero Therapeutics/$AKRO

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Akero Therapeutics

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

Ticker

$AKRO
Trading on

Industry

Biotechnology

Employees

60

AKRO Metrics

BasicAdvanced
$2.3B
Market cap
-
P/E ratio
-$3.74
EPS
-0.26
Beta
-
Dividend rate
$2.3B
-0.26
$37.00
$13.47
540K
17.253
16.568
4.867
4.867
-61.69%
-23.17%
-35.90%
3.05
3.05
-9.658
57.39%
9.88%

What the Analysts think about AKRO

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Akero Therapeutics stock.

AKRO Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

AKRO Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $AKRO

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Akero Therapeutics stock?

Akero Therapeutics (AKRO) has a market cap of $2.3B as of November 14, 2024.

What is the P/E ratio for Akero Therapeutics stock?

The price to earnings (P/E) ratio for Akero Therapeutics (AKRO) stock is 0 as of November 14, 2024.

Does Akero Therapeutics stock pay dividends?

No, Akero Therapeutics (AKRO) stock does not pay dividends to its shareholders as of November 14, 2024.

When is the next Akero Therapeutics dividend payment date?

Akero Therapeutics (AKRO) stock does not pay dividends to its shareholders.

What is the beta indicator for Akero Therapeutics?

Akero Therapeutics (AKRO) has a beta rating of -0.26. This means that it has an inverse relation to market volatility.